Patten Group Inc. Sells 654 Shares of Sanofi (NASDAQ:SNY)

Patten Group Inc. cut its holdings in shares of Sanofi (NASDAQ:SNY) by 3.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,879 shares of the company’s stock after selling 654 shares during the quarter. Patten Group Inc.’s holdings in Sanofi were worth $973,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in SNY. Boston Partners increased its stake in Sanofi by 0.3% during the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after acquiring an additional 33,657 shares during the period. Bank of New York Mellon Corp raised its stake in Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC lifted its position in Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares during the period. Mondrian Investment Partners LTD grew its stake in Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after buying an additional 1,190,141 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after buying an additional 246,224 shares during the period. 10.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

NASDAQ SNY opened at $55.15 on Thursday. The firm’s fifty day moving average price is $55.71 and its two-hundred day moving average price is $51.26. The stock has a market cap of $139.95 billion, a PE ratio of 27.71, a PEG ratio of 1.56 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. During the same quarter in the previous year, the company posted $0.95 EPS. Sanofi’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities analysts expect that Sanofi will post 4.26 EPS for the current fiscal year.

Analyst Ratings Changes

SNY has been the subject of a number of recent analyst reports. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Argus raised their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.